All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) smoker (current or former) smoker (Current) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
non squamous cell - mNSCLC - L1, anti-PD-(L)1 vs. atezolizumab plus carboplatin plus nab-paclitaxel, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-130 (all population), 2019 0.80 [0.65; 0.99]
0.80 [0.65 ; 0.99 ] IMpower-130 (all population), 2019 1 0% 723 NA not evaluable progression or deaths (PFS)detailed results IMpower-130 (all population), 2019 0.65 [0.54; 0.78]
0.65 [0.54 ; 0.78 ] IMpower-130 (all population), 2019 1 0% 723 NA not evaluable AE (any grade)detailed results IMpower-130 (all population), 2019 2.05 [0.29; 14.63]
2.05 [0.29 ; 14.63 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.72 [1.19; 2.47]
1.72 [1.19 ; 2.47 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable AE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 0.94 [0.47; 1.87]
0.94 [0.47 ; 1.87 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-130 (all population), 2019 1.27 [0.88; 1.85]
1.27 [0.88 ; 1.85 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable SAE (any grade)detailed results IMpower-130 (all population), 2019 1.69 [1.22; 2.32]
1.69 [1.22 ; 2.32 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable STRAE (any grade)detailed results IMpower-130 (all population), 2019 2.09 [1.35; 3.24]
2.09 [1.35 ; 3.24 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable TRAE (any grade)detailed results IMpower-130 (all population), 2019 2.00 [1.01; 3.95]
2.00 [1.01 ; 3.95 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.79 [1.28; 2.50]
1.79 [1.28 ; 2.50 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable TRAE leading to death (grade 5)detailed results IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
3.97 [0.49 ; 31.97 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Alopecia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.62 [1.11; 2.36]
1.62 [1.11 ; 2.36 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
1.48 [0.40 ; 5.52 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Constipation TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.86 [0.25; 2.95]
0.86 [0.25 ; 2.95 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.03 [0.49; 2.14]
1.03 [0.49 ; 2.14 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.02 [0.53; 1.96]
1.02 [0.53 ; 1.96 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.61 [0.52; 5.00]
1.61 [0.52 ; 5.00 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.22 [0.86; 1.72]
1.22 [0.86 ; 1.72 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.52 [0.83; 2.79]
1.52 [0.83 ; 2.79 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
1.48 [0.40 ; 5.52 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.23 [0.24; 6.38]
1.23 [0.24 ; 6.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Agranulocytosis (AE grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.47 [1.03; 2.11]
1.47 [1.03 ; 2.11 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 7.97 [0.46; 139.30]
7.97 [0.46 ; 139.30 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
1.59 [0.58 ; 4.39 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Back pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
3.97 [0.49 ; 31.97 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Colitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
2.96 [0.15 ; 59.25 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Constipation AE (grade 3-4)detailed results IMpower-130 (all population), 2019 4.95 [0.27; 90.93]
4.95 [0.27 ; 90.93 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Cough AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
2.96 [0.15 ; 59.25 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.33; 2.90]
0.98 [0.33 ; 2.90 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diabetes mellitus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.87 [0.44; 1.70]
0.87 [0.44 ; 1.70 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dizziness AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 5.61 [1.31; 24.06]
5.61 [1.31 ; 24.06 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Epistaxis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.28 [0.68; 2.43]
1.28 [0.68 ; 2.43 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.90 [0.33; 2.46]
0.90 [0.33 ; 2.46 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Gastritis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Headache AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.30; 7.38]
1.48 [0.30 ; 7.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.24; 3.96]
0.98 [0.24 ; 3.96 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.20; 2.62]
0.73 [0.20 ; 2.62 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.57 [0.66; 3.73]
1.57 [0.66 ; 3.73 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Myalgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Nausea AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
1.59 [0.58 ; 4.39 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Neutropenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.24 [0.88; 1.75]
1.24 [0.88 ; 1.75 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pancytopenia (AE grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.07; 3.49]
0.49 [0.07 ; 3.49 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Paraesthesia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.12; 4.42]
0.73 [0.12 ; 4.42 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.12; 4.42]
0.73 [0.12 ; 4.42 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.24; 3.96]
0.98 [0.24 ; 3.96 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.40 [0.67; 2.93]
1.40 [0.67 ; 2.93 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pneumonitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Rash AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.09; 10.87]
0.98 [0.09 ; 10.87 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Sepsis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 6.95 [0.39; 123.09]
6.95 [0.39 ; 123.09 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.02; 2.70]
0.24 [0.02 ; 2.70 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.49 [0.83; 2.69]
1.49 [0.83 ; 2.69 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.28 [0.45; 3.64]
1.28 [0.45 ; 3.64 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.09; 10.87]
0.98 [0.09 ; 10.87 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-30 01:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 307,165,163,176
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
